The latest price target for BridgeBio Pharma (NASDAQ:BBIO) was reported by Scotiabank on November 15, 2024. The analyst firm set a price target for $45.00 expecting BBIO to rise to within 12 months (a possible 91.49% upside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for BridgeBio Pharma (NASDAQ:BBIO) was provided by Scotiabank, and BridgeBio Pharma maintained their sector outperform rating.

There is no last upgrade for BridgeBio Pharma

The last downgrade for BridgeBio Pharma Inc happened on July 18, 2023 when Jefferies changed their price target from $24 to $33 for BridgeBio Pharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $44.00 to $45.00. The current price BridgeBio Pharma (BBIO) is trading at is $23.50, which is out of the analyst’s predicted range.